MedTrace Logo

Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva

NCT00598156 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 249

Last updated 2013-04-22

No results posted yet for this study

Summary

Chemotherapy and bevacizumab is given for 4 months. Patients who have not progressed will continue with maintenance treatment with either bevacizumab (Avastin) alone, or bevacizumab and erlotinib (Tarceva).

Conditions

Interventions

DRUG

erlotinib (Tarceva)

Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)

DRUG

bevacizumab (Avastin)

Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)

Sponsors & Collaborators

Principal Investigators

  • Anders Johnsson, MD PhD · Lund University Hospital, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-10-31
Completion
2012-08-31

Countries

  • Denmark
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00598156 on ClinicalTrials.gov